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Background: Deep-vein thrombosis (DVT) and pulmonary embolism (PE) are frequent and life-threatening
complications of ischemic stroke. We evaluated rates of symptomatic DVT/PE, and of in-hospital and post-discharge
thromboprophylaxis in patients with acute ischemic stroke (AIS).
Methods: In a retrospective US database analysis, data were extracted from the Premier Perspective™-i3 Pharma
Informatics linked database for patients aged ≥18 years who were hospitalized for ischemic stroke from January
2005 to November 2007, and who had ≥6 months’ continuous plan enrollment prior to index hospitalization.
Patients discharged to an acute-care facility or with atrial fibrillation were excluded. Prophylaxis was evaluated
during index hospitalization and for 14 days’ post-discharge. DVT/PE rates were calculated during index
hospitalization and up to 30 days post-discharge.
Results: A total of 1524 patients were included; 46.1% received pharmacological and/or mechanical prophylaxis
in-hospital (28.3%, 11.4% and 12.3% received unfractionated heparin, enoxaparin and mechanical prophylaxis,
respectively). 6.4% of patients received outpatient pharmacological prophylaxis; warfarin was most frequently
prescribed (5.9%). Total mean ± standard deviation length of index hospitalization was 3.0 ± 2.5 days. Mean
prophylaxis duration in all patients was 0.9 ± 1.5 days in-hospital and 1.7 ± 6.9 days post-discharge. Symptomatic
DVT/PE occurred in 25 patients overall (1.64%), with an inpatient rate of 0.98% and an outpatient rate of 0.66%.
Conclusions: Approximately 1% of patients with AIS experienced symptomatic in-hospital and/or post-discharge
DVT/PE. Although 46% received prophylaxis in-hospital, only 6% received prophylaxis in the outpatient setting. This
highlights the need for sustained thromboprophylaxis prescribing across the continuum of care.
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ThromboprophylaxisBackground
Deep-vein thrombosis (DVT) and pulmonary embolism
(PE) are frequent complications of ischemic stroke [1,2].
There is a large variation in incidence among different
clinical studies, with clinically confirmed DVT and PE in
patients with ischemic stroke without thromboprophylaxis
ranging from 1.0% to 5.2% and 0% to 5.6%, respectively
[3]. PE is an important cause of mortality in patients after
stroke; early studies indicated that PE accounted for up to* Correspondence: anamin@uci.edu
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reproduction in any medium, provided the ora quarter of premature deaths in the absence of prophy-
laxis [4,5]. In a more recent large registry study of 13 440
patients with ischemic stroke by Heuschmann et al., 0.4%
of patients developed PE and nearly half (46.8%) of these
patients died before hospital discharge [6].
Prophylaxis with low-molecular-weight heparins (LMWHs)
and unfractionated heparin (UFH) reduces the risk of
DVT in patients after acute ischemic stroke (AIS) [7-11].
Evidence-based guidelines from the American College of
Chest Physicians (ACCP) recommend that AIS patients
with restricted mobility receive LMWHs or UFH (Grade
1A) for the prevention of DVT/PE [12]. Although none oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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stroke patients per se, these patients are often categorized
as medical patients with reduced mobility—a group of
patients for which dalteparin and enoxaparin are indi-
cated. However, in real-world practice, many at-risk
patients with ischemic stroke do not receive any prophy-
laxis [13-17]. In the Post-Stroke Rehabilitation Outcomes
Project (PSROP), approximately a third of the 1161 at-risk
patients had no documented orders for anticoagulants
[16]. Even in those patients who do receive prophylaxis, it
is often inappropriate in terms of type, dose, and/or
duration [13-15], and this may limit its effectiveness at
preventing DVT/PE. The worldwide ENDORSE (Epide-
miologic International Day for the Evaluation of Patients
at Risk for Venous Thromboembolism in the Acute
Hospital Care Setting) study included 2423 patients with
ischemic stroke. Only 47.1% of at-risk patients received
any form of thromboprophylaxis and only 37.1% of
patients received prophylaxis in-line with ACCP recom-
mendations [13].
Patients with cerebrovascular disease spend on average
5.2 days in hospital [18]; therefore, outpatient prophy-
laxis may be required to enable the majority of patients
to receive the 8 to 16 day regimens that were effective in
clinical studies [7-11,19]. To understand current pre-
scribing practices, further investigations are required on
real-world use of thromboprophylaxis in patients with
AIS, both in-hospital and also post-discharge where
fewer data exist. There is also a need to assess actual
DVT/PE rates in inpatient and outpatient settings to
determine the current clinical burden associated with
DVT/PE. The objective of this analysis was to evaluate
symptomatic rates of DVT/PE events, and provision of
prophylaxis for DVT throughout the continuum of
care (in-hospital and post-discharge) in US patients
with AIS.
Methods
An observational, retrospective database analysis was per-
formed on national managed care data. As such, this study
was not governed by an Institutional Review Board. Data
were extracted from the Premier Perspective™-i3 Pharma
Informatics linked database, a large de-identified US hos-
pital clinical and economic database developed for quality
and utilization benchmarking. Claims data drawn from a
large national health plan were cross-matched on the indi-
vidual patient level for both in-hospital and post-discharge
records. Discharge records were included in the analysis if
patients met the following criteria: index hospitalization
between January 2005 and November 2007; age ≥ 18 years
at the time of index hospitalization; and ≥ 6 months’ con-
tinuous plan enrollment prior to the index hospitalization.
The 6-month period prior to index admission was used to
assess the presence of known risk factors for DVT/PE inthe patient history through medical claims. Patients also
had to be hospitalized for ischemic stroke as identified by
International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) code searches (codes
430.x, 431.x, 433.x1, 434.x1, 435.x, 436, and 362.3).
Patients were excluded if they had a length of hospital stay
of 0 days or > 30 days, had missing/unknown gender or
age data, or if they were diagnosed with atrial fibrillation.
Patients were also excluded if they were discharged or
transferred to an acute-care facility because outpatient
prescriptions for anticoagulants or DVT/PE readmissions
for these patients would not have been captured due to
treatment in another facility.
Inpatient prophylaxis, mechanical and/or pharmaco-
logical, was captured via charge codes during hospi-
talization. Outpatient pharmacological prophylaxis was
assessed as prescriptions during the 14-days prior to
index admission and the 14-days following index dis-
charge. Outpatient pharmacological prophylaxis was
allowed to be initiated up to 14-days before the index
admission to reflect that some patients might have
received their anticoagulation prescriptions prior to pre-
scheduled hospitalizations. Inpatient and outpatient
pharmacological prophylaxis was identified via charge
codes or pharmacy claims for UFH, LMWHs (enoxa-
parin, dalteparin, and tinzaparin), fondaparinux, and
warfarin. Pharmacological agents were considered
prophylactic if they were used at prophylaxis dosages
and used prior to any venous thromboembolism (VTE)
event. Mechanical prophylaxis was identified via charge
codes for graduated compression stockings (GCS) and
charge codes indicating the use of intermittent pneu-
matic compression devices and/or venous foot pumps.
Outpatient use of mechanical prophylaxis was not cap-
tured due to over-the-counter availability. Combination
prophylaxis usage was also analyzed, and was defined as
use of more than one product/type of prophylaxis across
the entire duration of the hospitalization or in the out-
patient setting. The presence or absence of prophylaxis
and the type used were calculated descriptively. The
mean ± s.d. length of hospitalization, and the duration of
inpatient and outpatient prophylaxis were also calcu-
lated; the prophylaxis duration was included as 0 for
patients receiving no prophylaxis.
Patients were followed for up to 30-days after discharge
in the analysis of symptomatic DVT/PE rates, and were
censored administratively at December 2007 or plan dis-
enrollment, whichever occurred first. Symptomatic DVT/
PE events were defined as the first diagnosis according to
ICD-9-CM codes and were categorized as index events
(primary or secondary diagnosis during index admission),
readmission events (primary or secondary diagnosis dur-
ing a hospital admission following index hospitalization),
or outpatient events (diagnosis in an outpatient setting
Table 1 Summary of patient demographics and
characteristics



















Urban location, n (%) 1413 (92.72)
Teaching hospital, n (%) 534 (35.04)
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14 days of diagnosis).
Results
A total of 1524 patients were included in the analysis
(Figure 1), with a mean ± s.d. age of 62.2 ± 12.2 years
(Table 1). Most patients were white (72.1%) and from
the south of the US (52.6%). The majority of patients
were commercially insured (91.1%) and were treated in
urban hospitals (92.7%), without teaching status (65.0%).
Less than half of the patients (46.1%) received any form
of thromboprophylaxis during the index hospitalization.
The most frequently prescribed pharmacological prophy-
lactic agents were UFH (28.3%) and enoxaparin (11.4%)
(Table 2). Other LMWHs and fondaparinux were
prescribed very infrequently. One in ten patients received
combination prophylaxis, and mechanical prophylaxis was
received by approximately an eighth of all patients.
Outpatient pharmacological prophylaxis was received by
6.4% of patients in the 14-day period post-discharge. The
most commonly prescribed post-discharge prophylactic
agent was warfarin (5.9%) (Table 2). Enoxaparin was the
only other pharmacological agent prescribed in the out-
patient setting (1.8%), most commonly in combination
with warfarin (1.3%).
The mean ± s.d. length of index hospitalization among
all AIS patients was 3.0 ± 2.5 days (Table 3). The mean
total duration of prophylaxis among all patients with
AIS was 2.6 ± 7.1 days, with a mean of 0.9 ± 1.5 days in
the inpatient setting and 1.7 ± 6.9 days in the outpatient
setting. The mean ± s.d. total duration among patients
who received in-hospital prophylaxis was 3.1 ± 6.5 days,Figure 1 Flow diagram of patient inclusions.with a mean duration of inpatient and outpatient
prophylaxis of 1.9 ± 1.6 days and 1.3 ± 5.9 days, respect-
ively (Table 3). Most patients who received prophylaxis
(77.0%) started initial inpatient prophylaxis on the first
day of hospitalization, with 16.1% of patients starting
prophylaxis on the second day of hospitalization. Over-
all, 54.1% of patients only received prophylaxis on the
day of hospital admission; 18.3% of patients received
prophylaxis up to the second day of hospitalization.
DVT/PE events occurred in 25 (1.64%) ischemic stroke
patients in this study (Figure 2), which included 5 PE
and 20 DVT events. Of these, 18 events occurred in
patients who had received VTE prophylaxis and 7 events
in patients who had not received VTE prophylaxis at
index. DVT/PE events during index hospitalization oc-
curred in 15 patients (0.98% of the total population; 60%
of the total events). Ten patients developed DVT/PE in
the outpatient setting (0.66%; 40% of the total events).
Overall, 5 patients (0.33%) were readmitted for DVT/PE
and 5 patients (0.33%) were treated for DVT/PE in the
30-day period post-discharge.
Discussion
In the present real-world study, a total of 25 out of 1524
ischemic stroke patients developed symptomatic DVT/
PE. The rate of PE of 0.33% is consistent with the PE
rate of 0.4% obtained in the German Stroke Registers
study by Heuschmann et al. [6]. In our study, 15
Table 2 Deep-vein thrombosis prophylaxis type in
ischemic stroke patients during hospitalization and in
the 14-day period post-discharge
Patients (n = 1524)
Index hospitalization, n (%)
Received any prophylaxis 703 (46.1)
Pharmacological prophylaxis 591 (38.8)






Combination prophylaxisa 153 (10.0)
Mechanical prophylaxis 187 (12.3)
Graduated compression stockings 60 (3.9)
Non-graduated compression stockings 148 (9.7)
Outpatient, n (%)
Received any prophylaxis 98 (6.4)







Combination pharmacological prophylaxisb 19 (1.3)
aUse of more than one product/type of prophylaxis across the entire duration
of the hospitalization.
bUse of more than one anticoagulant in the outpatient setting.
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risk in-hospital. In addition, 10 patients were readmitted
for DVT/PE or treated for DVT/PE in the outpatient
setting, demonstrating that the risk of the occurrence of
DVT/PE continues post-discharge. The risk of PE is
thought to persist for up to 4 weeks after stroke; in
patients who died in the second to fourth week after
stroke, PE was the dominant cause of death as verified
by autopsy [20].Table 3 Duration of hospital stay and prophylaxis
All ischemic stroke
patients (n = 1524)
Any pro
patients
Mean ± s.d. Median
(range)
Mean ± s.d.
Length of index hospital stay 3.0 ± 2.5 2 (1–27) 3.0 ± 2.7
Inpatient prophylaxis duration 0.9 ± 1.5 0 (0–12) 1.7 ± 1.7
Outpatient prophylaxis duration 1.7 ± 6.9 0 (0–42) 3.4 ± 9.4
Total prophylaxis duration 2.6 ± 7.1 1 (0–43) 5.1 ± 9.3In the present study, less than half of ischemic stroke
patients received any form of prophylaxis in hospital and
6% received pharmacological prophylaxis post-discharge.
These findings are consistent with several other studies
demonstrating suboptimal prescribing practices in
patients with ischemic stroke in-hospital [13-17]. The
current study did not investigate the appropriateness of
the prophylaxis provided but, given the results of other
studies in medical patients, it is likely that prophylaxis
was not in accordance with current guidelines in some
patients. Few studies have investigated outpatient prophy-
laxis prescribing in patients with ischemic stroke. The
present study analyzed anticoagulant prescriptions filled
post-discharge, but this may include patients receiving an
anticoagulant for reasons other than VTE prevention due
the recent hospitalization for stroke, such as for the se-
condary prevention of non-AF cardioembolic stroke or
dissection, or for atrial fibrillation developed after the
index hospitalization (patients with a diagnosis of atrial
fibrillation at the time of the index hospitalization were
excluded).
In the present study, inpatient prophylaxis with UFH
was received by approximately 30% of the ischemic
stroke patients, with one in ten patients receiving a
LMWH and an eighth receiving mechanical prophylaxis.
ACCP guidelines recommend pharmacological prophy-
laxis with a LMWH or UFH (Grade 1A) for patients
with reduced mobility after ischemic stroke [12]. Mechan-
ical prophylaxis with intermittent pneumatic compression
or GCS is only recommended for patients with contraindi-
cations to pharmacological prophylaxis (Grade 1B). Thigh-
length GCS failed to show a significant reduction in the
occurrence of symptomatic or asymptomatic proximal
DVT compared with avoidance of GCS after acute stroke
in the Clots in Legs Or sTockings after Stroke (CLOTS)
Trial 1 (10.0% vs. 10.5%, respectively; P = 0.88) [21]. How-
ever, thigh-length GCS were associated with fewer
instances of DVT (6.3%) after acute stroke than with
below-knee GCS (8.8%; P = 0.008), as observed in the
CLOTS Trial 2 [22].In the PREVAIL (PREvention of
Venous Thromboembolism After Acute Ischemic Stroke




patients (n = 703)
Outpatient prophylaxis
patients (n = 98)
Median
(range)
Mean ± s.d. Median
(range)
Mean ± s.d. Median
(range)
2 (1–27) 2.7 ± 2.2 2 (1–13) 5.2 ± 4.2 4 (1–27)
1 (0–12) 1.9 ± 1.6 1 (1–12) 1.2 ± 2.2 0 (0–9)
0 (0–42) 1.3 ± 5.9 0 (0–42) 27.0 ± 7.3 30 (2–42)
1 (0–43) 3.1 ± 6.5 1 (1–43) 28.2 ± 7.7 30 (3–43)
Figure 2 Deep-vein thrombosis (DVT)/pulmonary embolism (PE) rates during index hospitalization and rates in the outpatient setting
in the 30-day period after discharge.
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lowing 10 days’ (range 6 to 14 days) prophylaxis with the
LMWH enoxaparin, and 18% with UFH (relative risk 0.57;
95% confidence interval 0.44 to 0.76; P = 0.0001) [19]. The
occurrence of any bleeding complication was similar
between groups (both 8%; P = 0.83). The composite of
symptomatic intracranial and major extracranial hem-
orrhage was 1% in each group (P = 0.23), but there was a
slight, clinically significant, excess in major extracranial
hemorrhage alone with enoxaparin than UFH (1% vs. 0%;
P = 0.015).
In the current study, half of the patients who received
prophylaxis only received prophylaxis for 1 day—the first
day of hospitalization. For those patients who received
prophylaxis, the mean ± s.d. prophylaxis duration was
1.9 ± 1.6 days in the inpatient setting and 1.3 ± 5.9 days
in the outpatient setting (total 3.1 ± 6.5 days). Several
studies have shown reduced VTE risk with extended-
duration prophylaxis [3,19,23,24]. In the PREVAIL study,
10.5 ± 3.2 days’ prophylaxis duration was effective at re-
ducing DVT/PE events [19]. Although there are cur-
rently no guidelines regarding the most appropriate
duration of prophylaxis in stroke patients, there is still a
need for sustained use of prophylaxis across the con-
tinuum of care i.e. not only while hospitalized, but also
post-discharge.
National initiatives including performance measure
[25] and financial disincentives [26] have been developed
in the US to increase the use of prophylaxis in hospitals
in accordance with evidence-based guidelines, and to re-
duce the clinical and economic burden of VTE. Individ-
ual hospitals can also improve the care of ischemic stroke
patients by participating in quality initiatives such as the
“Get With The Guidelines-Stroke” program, [27] or by
implementing ‘standardized stroke orders’ [26]. Standar-
dized stroke orders involve multifaceted interventionsbased around preprinted discharge orders for stroke
patients [28]. After implementation of the stroke orders in
six hospitals, optimal DVT prophylaxis within 48 hours
significantly increased from 87% at year 1 to 96% by year
2 (P = 0.001) [28]. Registries have also been used as tools
to define deficiencies and improve quality of care. A volun-
tary web-based AIS registry was instigated and 50 hospitals
reported data on patients diagnosed with ischemic stroke
or transient ischemic attack [29]. Rates of optimal DVT
prophylaxis within 48 hours among patients with ischemic
stroke were found to increase from 76.4% in year 1 to
94.7% by year 4 (P = 0.01).
Although the Premier Perspective™-i3 Pharma In-
formatics linked databases provide real-world informa-
tion on approximately 275 000 unique patients across
the US, there are several limitations to the use of this
database for the current study. The database may not be
representative of the US ischemic stroke population as a
whole with regards to patient age and length of
hospitalization. A recent study suggests a trend for de-
creasing mean age of stroke as shown from 71.2 ±
13.5 years in 1993–1994 to 70.9 ± 14.5 years in 1999, and
to 68.4 ± 15.4 in 2005 [30]. Nevertheless, the mean age of
our population of patients with a hospitalization for stroke
was relatively low (62.2 ± 12.2 years), which could both
underestimate the risk of stroke and imply that the
patients included in our analysis experienced less severe
strokes. Furthermore, the average length of stay of our
population (3.0 ± 2.5 days) was shorter than reported pre-
viously (5.2 days). This could indicate that patients had
recovered mobility quickly following their stroke, and
therefore would not have been eligible for thrombopro-
phylaxis after discharge. However, due to the nature of
this database analysis, the level of reduced mobility in
patients could not be evaluated (either directly or indir-
ectly as a function of length of hospital stay). This limits
Amin et al. BMC Neurology 2013, 13:17 Page 6 of 7
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and doesn’t allow the assessment regarding the appropri-
ateness of prophylaxis (considering that the ACCP guide-
lines only recommend thromboprophylaxis for stroke
patients with restricted mobility). Another limitation of
this study is that pharmacological prophylaxis alone was
assessed in the outpatient setting. Outpatient use of mech-
anical prophylaxis, such as GCS, was not captured due to
over-the-counter availability. Furthermore, the rate of re-
admission for DVT/PE could be underestimated if
patients were readmitted to a hospital that is not included
in the database.
Conclusions
To conclude, this real-world study highlights the clinical
burden of DVT and PE in patients with ischemic stroke
both in-hospital and post-discharge. DVT prophylaxis
was used in 46% of in-hospital patients but only 6% of
outpatients. Our study is consistent with potentially in-
adequate frequency and duration of ‘real-world’ post-
stroke thromboprophylaxis.
Competing interests
Alpesh Amin has received research honorarium and is on the speakers
bureau for Sanofi U.S., Inc. Jay Lin is a former employee at Bruce Wong &
Associates, Inc., which received funding to carry out this work from Sanofi
U.S., Inc. Stephen Thompson is an employee of Sanofi U.S., Inc. Daniel
Wiederkehr was at the time of this analysis an employee at Quintiles
Consulting, which received funding to carry out this work from Sanofi U.S.,
Inc. Sanofi U.S., Inc is the manufacturer of enoxaparin (LovenoxW).
Authors’ contributions
ANA contributed to the study’s conception and design from a clinical
perspective and provided clinical expertise in interpreting the analyses; JL
and ST participated in the study design, data acquisition, and analysis and
interpretation of the data. DW collected the data, conducted statistical
analyses, wrote the study report, and participated in interpreting the re’sults.
All authors provided input and critical revision of the manuscript, and read
and approved the final version for submission.
Acknowledgments
Sanofi U.S., Inc provided funding to Quintiles Consulting to perform this
study. The authors received editorial/writing support in the preparation of
this manuscript from Hester van Lier, PhD, of Excerpta Medica, funded by
Sanofi U.S., Inc.
Author details
1Department of Medicine, University of California-Irvine, 101 The City Drive
South, Building 26, Room 1005, ZC-4076H, Orange, CA 92868, USA. 2Novosys
Health, Flemington, NJ, USA. 3Sanofi U.S., Inc, Bridgewater, NJ, USA. 4Pfizer
Inc, New York, NY, USA.
Received: 28 August 2012 Accepted: 29 January 2013
Published: 8 February 2013
References
1. Kelly J, Rudd A, Lewis R, Hunt BJ: Venous thromboembolism after acute
stroke. Stroke 2001, 32:262–267.
2. Kelly J, Rudd A, Lewis RR, Coshall C, Moody A, Hunt BJ: Venous
thromboembolism after acute ischemic stroke: a prospective study using
magnetic resonance direct thrombus imaging. Stroke 2004, 35:2320–2325.
3. Kamphuisen PW, Agnelli G, Sebastianelli M: Prevention of venous
thromboembolism after acute ischemic stroke. J Thromb Haemost 2005,
3:1187–1194.4. Bounds JV, Wiebers DO, Whisnant JP, Okazaki H: Mechanisms and timing
of deaths from cerebral infarction. Stroke 1981, 12:474–477.
5. Brown M, Glassenberg M: Mortality factors in patients with acute stroke.
JAMA 1973, 224:1493–1495.
6. Heuschmann PU, Kolominsky-Rabas PL, Misselwitz B, Hermanek P, Leffmann
C, Janzen RW, Rother J, Buecker-Nott HJ, Berger K, German Stroke Registers
Study Group: Predictors of in-hospital mortality and attributable risks of
death after ischemic stroke: the German Stroke Registers Study Group.
Arch Intern Med 2004, 164:1761–1768.
7. McCarthy ST, Turner J: Low-dose subcutaneous heparin in the prevention
of deep-vein thrombosis and pulmonary emboli following acute stroke.
Age Ageing 1986, 15:84–88.
8. Turpie AG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M,
Magnani HN, Hull RD, Gent M: Double-blind randomised trial of Org
10172 low-molecular-weight heparinoid in prevention of deep-vein
thrombosis in thrombotic stroke. Lancet 1987, 1:523–526.
9. Prins MH, Gelsema R, Sing AK, van Heerde LR, den Ottolander GJ: Prophylaxis
of deep venous thrombosis with a low-molecular-weight heparin (Kabi
2165/Fragmin) in stroke patients. Haemostasis 1989, 19:245–250.
10. Hillbom M, Erilä T, Sotaniemi K, Tatlisumak T, Sarna S, Kaste M: Enoxaparin vs
heparin for prevention of deep-vein thrombosis in acute ischaemic stroke:
a randomized, double-blind study. Acta Neurol Scand 2002, 106:84–92.
11. Diener HC, Ringelstein EB, von Kummer R, Landgraf H, Koppenhagen K,
Harenberg J, Rektor I, Csányi A, Schneider D, Klingelhöfer J, Brom J,
Weidinger G, PROTECT Trial Group: Prophylaxis of thrombotic and embolic
events in acute ischemic stroke with the low-molecular-weight heparin
certoparin: results of the PROTECT Trial. Stroke 2006, 37:139–144.
12. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P, American College of
Chest Physicians: Antithrombotic and thrombolytic therapy for ischemic
stroke: American College of Chest Physicians Evidence-Based Clinical
Practice Guidelines (8th Edition). Chest 2008, 133(6 Suppl):630S–669S.
13. Bergmann JF, Cohen AT, Tapson VF, Goldhaber SZ, Kakkar AK, Deslandes B,
Huang W, Anderson FA Jr, ENDORSE Investigators: Venous thromboembolism
risk and prophylaxis in hospitalised medically ill patients. The ENDORSE
Global Survey. Thromb Haemost 2010, 103:736–748.
14. Amin A, Stemkowski S, Lin J, Yang G: Thromboprophylaxis rates in US
medical centers: success or failure? J Thromb Haemost 2007, 5:1610–1616.
15. Amin A, Spyropoulos AC, Dobesh P, Shorr A, Hussein M, Mozaffari E, Benner
JS: Are hospitals delivering appropriate VTE prevention? The venous
thromboembolism study to assess the rate of thromboprophylaxis (VTE
start). J Thromb Thrombolysis 2010, 29:326–339.
16. Zorowitz RD, Smout RJ, Gassaway JA, Horn SD: Prophylaxis for and treatment
of deep venous thrombosis after stroke: the Post-Stroke Rehabilitation
Outcomes Project (PSROP). Top Stroke Rehabil 2005, 12:1–10.
17. Burleigh E, Wang C, Foster D, Heller S, Dunn D, Safavi K, Griffin B, Smith J:
Thromboprophylaxis in medically ill patients at risk for venous
thromboembolism. Am J Health Syst Pharm 2006, 63(20 Suppl 6):S23–S29.
18. DeFrances CJ, Cullen KA, Kozak LJ: National Hospital Discharge Survey:
2005 annual summary with detailed diagnosis and procedure data. Vital
Health Stat 2007, 165:1–209.
19. Sherman DG, Albers GW, Bladin C, Fieschi C, Gabbai AA, Kase CS, O’Riordan
W, Pineo GF, PREVAIL Investigators: The efficacy and safety of enoxaparin
versus unfractionated heparin for the prevention of venous
thromboembolism after acute ischaemic stroke (PREVAIL Study): an
open-label randomised comparison. Lancet 2007, 369:1347–1355.
20. Viitanen M, Winblad B, Asplund K: Autopsy-verified causes of death after
stroke. Acta Med Scand 1987, 222:401–408.
21. CLOTS Trials Collaboration, Dennis M, Sandercock PA, Reid J, Graham C,
Murray G, Venables G, Rudd A, Bowler G: Effectiveness of thigh-length
graduated compression stockings to reduce the risk of deep vein
thrombosis after stroke (CLOTS trial 1): a multicentre, randomised
controlled trial. Lancet 2009, 373:1958–1965.
22. CLOTS (Clots in Legs Or sTockings after Stroke) Trial Collaboration: Thigh-length
versus below-knee stockings for deep venous thrombosis prophylaxis after
stroke: a randomized trial. Ann Intern Med 2010, 153:553–562.
23. Harvey RL, Lovell LL, Belanger N, Roth EJ: The effectiveness of
anticoagulant and antiplatelet agents in preventing venous
thromboembolism during stroke rehabilitation: a historical cohort study.
Arch Phys Med Rehabil 2004, 85:1070–1075.
24. Turpie AG, Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Chen M,
Yusen RD, EXCLAIM Investigators: Venous thromboembolism risk in ischemic
Amin et al. BMC Neurology 2013, 13:17 Page 7 of 7
http://www.biomedcentral.com/1471-2377/13/17stroke patients receiving extended-duration enoxaparin prophylaxis: results
from the EXCLAIM study. Stroke 2012, doi:10.1161/STROKEAHA.112.659797.
25. The Joint Commission: Venous Thromboembolism (VTE) Core Measure Set.
http://www.jointcommission.org/assets/1/6/Venous%20Thromboembolism.pdf.
26. U.S. Department of Health & Human Services. Centers for Medicare &
Medicaid Services: Hospital-Acquired Conditions (Present on Admission
Indicator). http://www.cms.gov/HospitalAcqCond/01_Overview.
asp#TopOfPage.




28. California Acute Stroke Pilot Registry Investigators: The impact of
standardized stroke orders on adherence to best practices. Neurology
2005, 65:360–365.
29. Hills NK, Johnston SC: Duration of hospital participation in a nationwide
stroke registry is associated with improved quality of care. BMC Neurol
2006, 6:20.
30. Kleindorfer DO, Khoury J, Moomaw CJ, Alwell K, Woo D, Flaherty ML, Khatri
P, Adeoye O, Ferioli S, Broderick JP, Kissela BM: Stroke incidence is
decreasing in whites but not in blacks: a population-based estimate of
temporal trends in stroke incidence from the Greater Cincinnati/
Northern Kentucky Stroke Study. Stroke 2010, 41:326–1331.
doi:10.1186/1471-2377-13-17
Cite this article as: Amin et al.: Rate of deep-vein thrombosis and
pulmonary embolism during the care continuum in patients with acute
ischemic stroke in the United States. BMC Neurology 2013 13:17.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
